BMS Brings the Buzz Around Late-Stage Readouts Amid a So-So Q1

Why It Matters

Late‑stage data could replace Eliquis and sustain BMS’s revenue trajectory, crucial as key patents expire. The outcomes will shape investor confidence and competitive dynamics in oncology, cardiovascular and neuroscience markets.

Key Takeaways

• Milvexian Phase III readouts slated for 2024, could replace Eliquis.
• Camzyos revenue jumped 97% to $314 m, boosting growth portfolio.
• BMS Q1 revenue rose 1% to $11.5 bn, beating forecasts.
• Cobenfy revenue up 107% to $56 m, adoption remains slow.
• 2026 guidance remains $46‑$47.5 bn, underscoring long‑term outlook.

Pulse Analysis

Bristol Myers Squibb is navigating a pivotal inflection point as its flagship anticoagulant Eliquis approaches a 2027 patent cliff. Investors are watching the company’s late‑stage pipeline, especially milvexian, a factor Xa inhibitor positioned to deliver comparable efficacy with a better bleeding profile. If Phase III trials confirm these advantages, milvexian could become the next blockbuster, preserving BMS’s cardiovascular franchise and offsetting the revenue erosion expected from Eliquis’s loss of exclusivity.

Beyond anticoagulation, BMS’s neuroscience assets are gaining attention. Cobenfy, approved for schizophrenia, posted a 107% revenue surge to $56 m, yet physician uptake remains cautious, particularly in the U.S. market. The drug’s broader potential—spanning Alzheimer’s psychosis, bipolar‑I, and agitation—relies on a series of pivotal trials slated between 2026 and 2029. Meanwhile, Camzyos, targeting obstructive hypertrophic cardiomyopathy, delivered a 97% year‑on‑year revenue jump to $314 m, illustrating how niche indications can fuel growth when larger patents wane.

Financially, BMS posted a modest 1% YoY revenue increase to $11.5 bn and beat EPS expectations with $1.58 per share. The growth portfolio’s 9% expansion to $6.2 bn, anchored by Camzyos and emerging candidates, helped sustain momentum. By reaffirming its 2026 revenue target of $46‑$47.5 bn, BMS signals confidence in its pipeline’s ability to deliver long‑term value. The upcoming readouts will be a litmus test for the company’s strategy to replace aging blockbusters and maintain its standing in a competitive pharma landscape.